Jefferies downgraded Esperion to Hold from Buy with a price target of $3.28, down from $5, after the company announced it will be acquired by Archimed for $3.16 per share and a $100M contingent value right. The sees this as \"a good outcome\" ahead of major competitive headwinds over the next 6-18 months, the analyst tells investors.
